Avistone of Beijing Raises $200 Million; Will Combine with Pearl Biotech

Beijing Avistone Pharma, a precision oncology company, received a more than $200 million strategic investment led by Vivo Capital. The capital will support the combination of Avistone and Pearl Biotech, which is also based in Beijing . The two companies plan to create a fully-integrated targeted oncology platform. Avistone's lead drug is a c-Met inhibitor in late-stage clinical development for genetically-defined patients with non-small cell lung cancer and glioblastoma. Bain Capital and Primavera Capital also participated in the investment. More details.... Share this with colleagues: // //